Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.
Doudna lab finds chromosome loss from CRISPR-Cas9 is common—and swapping steps is key to stopping it
When it comes to solving math problems, the order of operations matters (PEMDAS, from left to right!). That appears to be the case for engineering T cells with CRISPR-Cas9, too, as new research from ...
Vertex and CRISPR Therapeutics’ dream of getting the first-ever CRISPR gene editing therapy approved now seems within reach as the candidate aced primary endpoints in a pair of phase 3 trials mere ...
The first in-human trial of a CRISPR Cas system delivered by adeno-associated virus 9 gene therapy to treat HIV was able to target only the intended DNA and cleared the blood within 6 months.
Crispr Therapeutics ((CRSP)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback